Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial

Official title:

Pilot Study of the Safety and Efficacy of Anti-FLT3 Chimeric Antigen Receptor Engineered T-Cells in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05023707
• Other study ID #: 2021136
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 31, 2021
• Est. completion date: June 30, 2025

Study information

• Verified date: July 2021
• Source: The First Affiliated Hospital of Soochow University
• Contact: Xiaowen Tang, Ph.D
• Phone: (0086)51267781856
• Email: xwtang1020[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective,open-label, phase1/2 study to evaluate the safety and efficacy of anti-FLT3 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of FLT3 positive relapsed or refractory acute myeloid leukemia.

Description:

The patients will receive infusion of anti-FLT3 CAR T-cells targeting FLT3 to evaluate the safety and efficacy of anti-FLT3 CAR T-Cells in relapsed or refractory acute myeloid leukemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 65 Years

Eligibility

Inclusion Criteria:

• FLT3 positive relapsed/refractory acute myeloid leukemia
• Age 16-65 years.
• Left ventricular ejection fractions = 0.5 by echocardiography
• Creatinine < 1.5x upper limit of normal.
• Aspartate aminotransferase/aspartate aminotransferase = 2.5x upper limit of normal
• Total bilirubin = 1.5x upper limit of normal
• Karnofsky performance status = 60
• Expected survival time = 3 months (according to investigator's judgement)

Exclusion Criteria:

• Patients are pregnant or lactating
• Uncontrolled active infection
• Grade III/IV cardiovascular disability according to the New York Heart
• Association Classification
• Active hepatitis B or hepatitis C infection
• Patients with HIV infection
• Patients with a history of seizure
• Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement)

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Biological:
• anti-FLT3 CAR-T
Single intravenous infusion of anti-FLT3 CAR-T cells

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu

Sponsors (5)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Soochow University	Huai'an Second People's Hospital, PersonGen BioTherapeutics (Suzhou) Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events	Adverse events are evaluated with CTCAE V5.0	12 months
Secondary	Overall response rate (ORR)	ORR includes CR, CRi, MLFS and PR. Complete remission (CR):Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count >1.0x 10^9/L; platelet count >100x10^9/L. CR with incomplete hematologic recovery (CRi):All CR criteria except for residual neutropenia (<1.0 x 109/L) or thrombocytopenia (<100 x 109/L). Morphologic leukemia-free state (MLFS): Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.	2 years
Secondary	Event-free survival (EFS)	time from enrollment to the date of primary refractory disease, or relapse from CR or CRi, or death from any cause	2 years
Secondary	Cumulative incidence of relapse(CIR)	time from the date of achievement of a remission until the date of relapse	2 years